https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2020-03-16 17:41:482020-05-20 11:33:51Prof. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zur Immuntherapie
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-16 / Biomedicines 2020 Mar;8(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-16 / Biomedicines 2020 Mar;8(3)2020-03-16 00:00:002021-11-15 19:52:47Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-06 / Biomedicines 2020 Mar;8(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-06 / Biomedicines 2020 Mar;8(3)2020-03-06 00:00:002021-11-15 17:52:40New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-08-30 / Biomedicines 2019 Aug;7(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-2051
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-20512019-04-01 00:00:002021-11-15 20:00:34Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-10 / Int J Oncol 2019 Feb;54(2):407-419
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-10 / Int J Oncol 2019 Feb;54(2):407-4192018-12-10 00:00:002021-11-15 20:14:26From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2018-12-01 18:15:082021-11-15 17:54:58International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-01 / Lancet Oncol 2018 08;19(8):e419-e428
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-01 / Lancet Oncol 2018 08;19(8):e419-e4282018-08-01 00:00:002021-11-15 19:56:02Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
root
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
root2018-07-24 18:56:262020-05-27 11:18:50IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2018-01-01 16:18:592019-02-10 11:33:47Buch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy
